225 related articles for article (PubMed ID: 26718011)
1. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Mikyšková R; Štěpánek I; Indrová M; Bieblová J; Šímová J; Truxová I; Moserová I; Fučíková J; Bartůňková J; Špíšek R; Reiniš M
Int J Oncol; 2016 Mar; 48(3):953-64. PubMed ID: 26718011
[TBL] [Abstract][Full Text] [Related]
2. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.
Mikyskova R; Indrova M; Stepanek I; Kanchev I; Bieblova J; Vosahlikova S; Moserova I; Truxova I; Fucikova J; Bartunkova J; Spisek R; Sedlacek R; Reinis M
Oncoimmunology; 2017; 6(12):e1362528. PubMed ID: 29209567
[TBL] [Abstract][Full Text] [Related]
4. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
5. High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy.
Urbanova L; Hradilova N; Moserova I; Vosahlikova S; Sadilkova L; Hensler M; Spisek R; Adkins I
Immunol Lett; 2017 Jul; 187():27-34. PubMed ID: 28495513
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.
De Sanctis F; Sandri S; Martini M; Mazzocco M; Fiore A; Trovato R; Garetto S; Brusa D; Ugel S; Sartoris S
Vaccine; 2018 Jun; 36(25):3708-3716. PubMed ID: 29752021
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
[TBL] [Abstract][Full Text] [Related]
8. High hydrostatic pressure induces immunogenic cell death in human tumor cells.
Fucikova J; Moserova I; Truxova I; Hermanova I; Vancurova I; Partlova S; Fialova A; Sojka L; Cartron PF; Houska M; Rob L; Bartunkova J; Spisek R
Int J Cancer; 2014 Sep; 135(5):1165-77. PubMed ID: 24500981
[TBL] [Abstract][Full Text] [Related]
9. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
[TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells induce specific cytotoxic T lymphocytes against prostate cancer TRAMP-C2 cells loaded with freeze- thaw antigen and PEP-3 peptide.
Liu XQ; Jiang R; Li SQ; Wang J; Yi FP
Asian Pac J Cancer Prev; 2015; 16(2):571-8. PubMed ID: 25684489
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines.
Simova J; Sapega O; Imrichova T; Stepanek I; Kyjacova L; Mikyskova R; Indrova M; Bieblova J; Bubenik J; Bartek J; Hodny Z; Reinis M
Oncotarget; 2016 Aug; 7(34):54952-54964. PubMed ID: 27448982
[TBL] [Abstract][Full Text] [Related]
17. Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model.
Mackiewicz J; Kazimierczak U; Kotlarski M; Dondajewska E; Kozłowska A; Kwiatkowska E; Nowicka-Kotlarska A; Dams-Kozłowska H; Wysocki PJ; Mackiewicz A
Anticancer Res; 2015 Jun; 35(6):3275-88. PubMed ID: 26026087
[TBL] [Abstract][Full Text] [Related]
18. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.
Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH
Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090
[TBL] [Abstract][Full Text] [Related]
19. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
20. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
